Evolocumab, a monoclonal antibody used for the treatment of hyperlipidemia or elevated levels of cholesterol and other lipoproteins, binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing its interaction with low-density lipoprotein receptors to reduce circulating cholesterol and other lipoproteins.

Bio-Rad's sequence-defined, recombinant antibodies inhibit the binding of evolocumab to its target human PCSK9, a protein that has been shown to play a key role in the regulation of cholesterol levels. These antievolocumab antibodies are suitable for developing highly selective and sensitive pharmacokinetic (PK) and antidrug antibody (ADA) assays for evolocumab and its biosimilars, according to the company.

The antibodies can be used to develop PK-bridging enzyme-linked immunosorbent assays to measure free drug or as a surrogate positive control or reference standard in an ADA assay. The new range of five antievolocumab antibodies includes fully human immunoglobulin G1 (IgG1) clones and TrailBlazer Antibodies with a SpyTag incorporated into their heavy chain, enabling site-directed conjugation or fast-switching to a bivalent fragment antigen-binding (Fab) or a full-length Ig-like format within an hour.